Today: 2 July 2026
Browse Category

NYSE:LLY 9 February 2026 - 21 April 2026

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly on Monday agreed to buy Boston’s Kelonia Therapeutics in a deal valued at up to $7 billion in cash, adding a fresh in vivo cell therapy play to its pipeline. The drugmaker will pay $3.25 billion upfront, with the balance subject to hitting clinical, regulatory, and commercial milestones. This counts for Lilly, which is currently pouring cash into expanding outside its obesity business—even as rivals close in on the weight-loss drug market. The deal hands Lilly a stronger foothold in oncology too. IQVIA projects worldwide cancer drug spending could jump from about $223 billion last year to $409 billion by 2028.
21 April 2026
··
Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly kicks off the week with a fresh pipeline pact in hand. Insilico Medicine on Sunday announced it struck a global licensing and research deal with the U.S. pharma giant, a tie-up valued at as much as $2.75 billion. Lilly shares finished Friday at $878.24, off 2.1%. The stock sits more than 22% beneath its Jan. 8 peak. The timing is key here: Lilly is out to show it can stretch its growth well past its headline-grabbing weight-loss and diabetes drugs. Earlier this month, CFO Lucas Montarce told investors the company’s oral obesity drug orforglipron was “on track in the US” for a possible second-quarter launch. All this comes as Wall Street analysts are pulling back peak sales estimates for the obesity-drug sector, citing lower U.S. prices.
29 March 2026
··
Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly shares grabbed attention Thursday, with the drugmaker reporting its experimental obesity and diabetes therapy, retatrutide, hit the primary endpoint in a late-stage trial—showing notable drops in both weight and blood sugar. The stock last changed hands at $918.05, off 1.3% early, after Tuesday’s nearly 6% tumble that followed a rare downgrade from HSBC. Timing is a factor here. Investors are watching to see if Lilly can keep converting clinical successes into real growth, now that the obesity-drug focus has moved from supply constraints to pricing and reimbursement questions. The cash-pay segment—patients buying out of pocket, without insurance—adds another wrinkle. Lilly is also awaiting a U.S. ruling on orforglipron, its oral obesity candidate. Chief Financial Officer Lucas Montarce said earlier this month the drug was “on track in the US” and could hit the market as soon as the second quarter.
19 March 2026
···
Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket action as of 9:00 a.m. EDT on Thursday, following a 10.3% jump to $25.88 at Wednesday’s close. That put the telehealth company on track for its fourth consecutive advance. This surge traces back to a shift in Hims’ weight-loss strategy—not just a flash of momentum. The company locked in a new agreement with Novo Nordisk, settling their patent fight and putting FDA-approved Wegovy and Ozempic back in Hims’ lineup. As a result, Hims will largely drop compounded GLP-1 offerings, moving further from pharmacy-crafted alternatives in favor of the branded drugs that treat obesity and diabetes. Hims says Novo’s treatments hit the platform later this month.
12 March 2026
···
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

NORTH CHICAGO, Illinois, March 10, 2026, 14:19 CDT. AbbVie said on Monday its experimental obesity drug ABBV-295 helped adults lose up to 9.79% of their body weight in 12 weeks in an early-stage study, giving the drugmaker its clearest sign yet that it may have a contender in a market led by Eli Lilly and Novo Nordisk. The company said no serious adverse events were reported.
10 March 2026
····
Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

New York, February 27, 2026, 19:03 — After-hours Shares of Eli Lilly and Company jumped 2.93% to finish at $1,051.99 on Friday, breaking a three-session slump and pulling ahead of a broader market that dropped. The S&P 500 slipped 0.43%, while the Dow lost 1.05%, as traders grappled with stretched valuations and renewed jitters over the speed of artificial intelligence’s impact on market leaders and laggards.
28 February 2026
···
Eli Lilly stock price: $1.5 billion pill inventory puts April 10 FDA decision in spotlight

Eli Lilly stock price: $1.5 billion pill inventory puts April 10 FDA decision in spotlight

New York, Feb 15, 2026, 11:43 — The market wrapped up for the day. Eli Lilly and Company shares will be in the spotlight again when U.S. markets open Tuesday. The company revealed a $1.5 billion pre-launch inventory buildup for its oral weight-loss candidate, orforglipron. The stock last changed hands at $1,040.00, up roughly 0.2% from the previous finish. With markets closed Monday for Presidents Day, investors get one more day to process the update.
15 February 2026
··
Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

New York, February 12, 2026, 11:40 a.m. EST — Regular session Eli Lilly and Company climbed almost 2% Thursday, pushing its rebound further as the company reported new regulatory progress for mirikizumab in China—a drug aimed at inflammatory bowel disease. By late morning, shares traded at $1,033.23, up 1.8%. The Health Care Select Sector SPDR Fund posted modest gains. Novo Nordisk’s U.S. shares, however, slipped.
12 February 2026
··
1 2 3 4 … 13

Stock Market Today

  • AI and Chip Stocks Fall as Market Takes a Hit
    July 2, 2026, 7:27 AM EDT. AI and semiconductor shares dropped, putting pressure on the wider market. Chip names, key plays in tech and AI, are usually seen as a market sentiment gauge. If losses keep up in these sectors, it could point to deeper worries for investors and shake confidence more broadly.
Go toTop